Africa Targets 60% Local Medicine Production by 2040 as Ruto Challenges Continental Dependency
Nairobi, 14 February 2026
President William Ruto’s bold call for African pharmaceutical independence could reshape the continent’s $36 billion healthcare market, projected to exceed $122 billion by 2032. Speaking at the African Union summit on 14 February 2026, Ruto highlighted Africa’s paradox: over 570 registered health manufacturers yet continued reliance on imported medicines that strain budgets and compromise health security. With only nine national authorities meeting WHO standards and 27 vaccine initiatives underway, Africa plans an Extraordinary Summit on Local Manufacturing in April 2026 to accelerate progress towards producing 60% of health products locally by 2040.
Continental Health Security at Stake
The Kenyan president’s intervention comes at a critical juncture for Africa’s healthcare landscape. Speaking on 14 February 2026 at the African Union meeting in Addis Ababa, Ruto warned that Africa’s heavy reliance on imported medicines fundamentally compromises health security and places unsustainable pressure on national budgets [1]. His remarks reflect a growing consensus among African leaders that the continent’s current position as a net consumer in the global health economy leaves vulnerable populations, including refugees, exposed to supply chain disruptions and price volatility. The timing of these discussions, coinciding with ongoing health challenges across East Africa, underscores the urgency of building resilient healthcare systems that can serve both host communities and displaced populations effectively.
Market Dynamics and Growth Projections
The financial implications of Ruto’s pharmaceutical independence agenda are substantial. Africa’s pharmaceutical market, valued at approximately $36 billion in 2023, is projected to exceed $122 billion by 2032 [1]. This represents a potential growth rate of 238.889 per cent over the nine-year period, highlighting the enormous economic opportunity that local manufacturing could capture. However, the continent currently operates over 570 registered health product manufacturers alongside more than 27 ongoing vaccine manufacturing initiatives [1]. Despite this existing infrastructure, fragmented procurement systems continue to undermine local manufacturers’ viability. As Ruto emphasised during his address: ‘Without predictable and aggregated markets, local manufacturers cannot scale or remain viable. Pooled procurement is therefore not optional; it is necessary’ [1].
Regulatory Framework and Quality Standards
The path to pharmaceutical self-sufficiency requires robust regulatory oversight, an area where Africa has made notable progress. Currently, nine national authorities meet the World Health Organisation’s Maturity Level 3 standards, whilst the African Medicines Agency has become operational [1]. This regulatory infrastructure provides the foundation for ensuring that locally manufactured medicines and vaccines meet international quality standards. For refugee populations and host communities in regions like Turkana, this development is particularly significant as it promises more reliable access to essential medications without the delays and cost fluctuations associated with international supply chains. The establishment of harmonised standards across the continent will be crucial for creating the regional value chains that Ruto advocates.
Strategic Roadmap and Implementation Timeline
The African Union has outlined an ambitious timeline for achieving pharmaceutical independence. An Extraordinary Summit on Local Manufacturing is scheduled for April 2026, which will serve as a critical milestone for coordinating continental efforts [1]. The overarching goal remains clear: Africa aims to produce at least 60% of its health products locally by 2040 [1]. This target represents a fundamental shift from the current model where, as Ruto noted, Africa continues to export raw materials whilst importing finished products [1]. The president’s call for regional value chains reflects recognition that no single African nation can achieve pharmaceutical self-sufficiency in isolation. For refugee-hosting regions, this coordinated approach could ensure more stable medicine supplies during humanitarian crises, reducing the vulnerability of displaced populations to external supply shocks.